Given that oxaliplatin is also a standard chemotherapeutic agent used in colon cancer treatment, we also examined the expression of molecular signature genes PIK3CA, SLC6A6, ASAP-1 and TMEM-43 in colon cancer cells resistant to this drug. This evidence concerns the gene SLC6A6 and malignant colon neoplasm.